The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for ...
Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...
The FDA’s clearance of this expanded label enables access to Deep TMS™ for the critically important adolescent patient ...
To provide some solid data, the authors of the new study gave LSD to a group of patients in New Zealand, and instructed them ...
Whether you live with bipolar disorder or major depressive disorder, you experience periods of depression. This can make it hard to tell them apart. But the bi-in bipolar means “two” because it has ...
MedPage Today on MSN
FDA Broadens Caplyta Approval to Include Major Depression
The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive ...
As the country continues to grapple with a mental health crisis, it may not be a surprise to learn that according to the National Institute of Mental Health, more than 21 million American adults have ...
BrainsWay announced today that the FDA granted a label expansion for its deep transcranial magnetic stimulation (Deep TMS) ...
The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...
The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to induce electrical currents in localized regions of the prefrontal cortex.
University of Auckland researchers report that an 8-week, twice-weekly LSD microdosing regimen for major depressive disorder ...
The FDA has approved Caplyta as adjunctive therapy with antidepressants to treat major depressive disorder in adults, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback